Benign Prostatic Hyperplasic Devices Market Analysis and Forecast to 2031: By Procedure Type (Transurethral Resection of the Prostatic, Transurethral Microwave Therapy, Transurethral Needle Ablation of the Prostatic, Laser Surgery, Prostatic Stenting), En

Benign Prostatic Hyperplasic Devices Market Analysis and Forecast to 2031: By Procedure Type (Transurethral Resection of the Prostatic, Transurethral Microwave Therapy, Transurethral Needle Ablation of the Prostatic, Laser Surgery, Prostatic Stenting), End User (Hospitals & Clinics, Ambulatory Surgical Centers), and Region

The global benign Prostatic hyperplasic devices market was valued at USD 2078.0 million in 2021 and it is anticipated to grow further till USD 4317.5 million by 2031, at a CAGR of 7.6% during the forecast period.

Benign prostatic hyperplasia is a non-cancerous (benign) endocrine growth that may make urination difficult. Men get benign prostatic hyperplasia (BPH) more frequently as they age, especially after the age of 50. Although the exact reason is unknown, hormone changes, particularly those brought on by dihydrotestosterone and testosterone, are most likely to be to blame. BPH is a Prostatic enlargement that affects 110 million men worldwide. Prostatic adenoma cells produce extra tissue, which can lead to symptoms that have an adverse effect on a patient's quality of life, such as a constant, urgent need to urinate.

Global Benign Prostatic Hyperplasic Devices Market Scope and Report StructureMarket Trends and Drivers

The ageing population, rising demand for minimally invasive treatments, and ongoing technological improvements have all contributed to the creation of BPH devices of the highest possible quality and safety. Furthermore, the development of less invasive BPH methods with improved safety and efficacy has been aided by technology improvements.

Men's Prostatics may grow with age and limit or stop urine flow. The National Institute on Aging reports that the global geriatric population was 8.5% in 2015 and is projected to increase to 17% by 2050. These statistics demonstrate the increasing demand for home infusion therapy among a population that is at high risk. 90% of men in their 70s and 80s, as well as more than half of all men in their 60s.

Market Restraints and Challenges

The urological devices industry, like all other industries, is constrained by a variety of market factors. For instance, the high cost of the majority of urological devices restricts not only those who cannot afford healthcare but also the market for urology devices. The global market size for urological devices can grow even more by expanding its customer base if the industry strives to overcome this constraint. Once the cost constraint in the market is removed, customers would find life easier.

Global Benign Prostatic Hyperplasic Devices Market Segmental Overview

The report analyses the global benign Prostatic hyperplasic devices market based on the procedure type, end user, and regions.

Global Benign Prostatic Hyperplasic Devices Market by Procedure Type

Based on the procedure type, it is segmented into transurethral resection of the Prostatic, prostatic urethral lift, Prostatectomy, laser surgery, transurethral microwave therapy, transurethral needle ablation of the Prostatic, and prostatic stenting/implants. The transurethral resection of the Prostatic segment is anticipated to dominate the market during the forecast period. Surgery called transurethral resection of the Prostatic (TURP) is performed to treat urinary issues brought on by an enlarged Prostatic. A surgical procedure called transurethral resection of the Prostatic (TURP) is used to remove an extra portion of the Prostatic gland that is obstructing normal urine flow. TURP has some benefits over other lower urinary tract infection treatments, including visual, hands-on access to the Prostatic, immediate removal of extra tissue, and ability to combine with other procedures.

Global Benign Prostatic Hyperplasic Devices Market by End User

Based on the end user, it is segmented into hospital & clinics, and ambulatory surgical centers. The hospital segment is anticipated to dominate the market during the forecast period. Due to the increase in procedures conducted in hospitals, the availability of cutting-edge medical facilities, and the increased affordability of treatment as a result of the increase in disposable income. The demand for prostatic hyperplasia devices in ambulatory surgical centres is also rising as a result of the several advantages that these facilities provide, including short stays, cost-effectiveness, and a lower risk of hospital-acquired infections.

Geographical Analysis of the Global Benign Prostatic Hyperplasic Devices Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America region is anticipated to dominate the market during the forecast period. The high prevalence of benign prostatic hyperplasia and growing geriatric population in the North American region are primarily responsible for the considerable proportion. However, Asia is the region with the greatest market growth because of the rise in urological problems and illnesses, as well as the region's expanding elderly population and public awareness campaigns.

Major Players in the Global Benign Prostatic Hyperplasic Devices Market

The key players studied in the report are

COVID-19 Impact

The COVID 19 epidemic may have negatively impacted every other industry, but the market for urology devices was the only one that benefited. The COVID 19 epidemic has increased attention to both individual and societal health. The COVID 19 virus is not the only concern among the general public. In reality, society as a whole has become more health-conscious. People have stayed in and prioritised their health and wellbeing. Including urological health in this. Because health services are not readily available, people have begun keeping medical equipment at home.

Recent Developments

• April 2022, Teleflex announced the launch of the UroLift system in Japan for the treatment of benign prostatic hyperplasia. The FDA had cleared the usage of UroLift system for treating lower urinary tract symptoms owing to benign prostatic hyperplasia.
• March 2021, Olympus exercises, a Japan based company manufacturer of optics and reprography products acquired Medi-Tate for an undisclosed amount. This acquisition of Medi-Tate to drive growth in its urology business and expand its minimally invasive treatment product portfolio.

Frequently Asked Questions

Q1. How big is the Benign Prostatic Hyperplasic Devices market?Ans. The global Benign Prostatic Hyperplasic Devices market size was USD 2078.0 million in 2021 and it is anticipated to grow further till USD 4317.5 million by 2031, at a CAGR of 7.6% from 2022 to 2031.Q2. What is the Benign Prostatic Hyperplasic Devices market growth rate?Ans. The growth rate of the Benign Prostatic Hyperplasic Devices market is 7.6%.Q3. Which Ans. North America holds a major market share of the Benign Prostatic Hyperplasic Devices market in 2021.Q4. Which segment accounted for the largest Benign Prostatic Hyperplasic Devices market share?Ans. By End User, the hospitals segment accounted for the largest Benign Prostatic Hyperplasic Devices market share.Q5. Who are the key players in the Benign Prostatic Hyperplasic Devices market?Ans. The global Benign Prostatic Hyperplasic Devices market report includes players such as Q6. What are the factors driving the Benign Prostatic Hyperplasic Devices market growth?Ans. The major factors driving the growth of the market are the growing healthcare market in emerging countries.Q7. What are the key growth strategies of Benign Prostatic Hyperplasic Devices market players?Ans. The key growth strategies of Benign Prostatic Hyperplasic Devices market players are product launch and product approval.Q8. Which Ans. The Asia-Pacific region will provide more business opportunities for the Benign Prostatic Hyperplasic Devices market during the forecast period.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.